APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

α-Glucosidase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global α-Glucosidase Inhibitors Industry Growth and Trends Forecast to 2032

Report ID 173995690120 December 2025125 pages

Choose your research edition.

Industry Researchα-Glucosidase Inhibitors Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal α-Glucosidase Inhibitors Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal α-Glucosidase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal α-Glucosidase Inhibitors Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal α-Glucosidase Inhibitors Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global α-Glucosidase Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for α-Glucosidase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for α-Glucosidase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for α-Glucosidase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of α-Glucosidase Inhibitors include Bluepharma, Glenmark Pharma, Lunan Pharma, Lupin Pharma, Strides Pharma, Bayer, Beijing SL Pharmaceutical, Cisen Pharmaceutical and Hangzhou East China Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global α-Glucosidase Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The α-Glucosidase Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global α-Glucosidase Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to α-Glucosidase Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global α-Glucosidase Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

α-Glucosidase Inhibitors Market by Company

Bluepharma

Glenmark Pharma

Lunan Pharma

Lupin Pharma

Strides Pharma

Bayer

Beijing SL Pharmaceutical

Cisen Pharmaceutical

Hangzhou East China Pharmaceutical

Pfizer

Jinri Pharmaceutical (China)

Livzon Pharm

Luye Pharma

Nanjing Hicin Pharmaceutical

Shandong New Time Pharmaceutical

CSPC Ouyi Pharmaceutical

Weiao Pharmaceutical (Sichuan)

Sun Pharmaceutical

SUN Pharma

Takeda

YaoPharma

Zhejiang Hisun Pharmaceutical

Zhejiang Jingxin Pharmaceutical

Zhejiang Medicine

α-Glucosidase Inhibitors Segment by Type

Acarbose

Voglibose

Miglitol

Other

α-Glucosidase Inhibitors Segment by Application

Hospital and Clinic

Pharmacy

Other

α-Glucosidase Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global α-Glucosidase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of α-Glucosidase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of α-Glucosidase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of α-Glucosidase Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of α-Glucosidase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Acarbose Table 2. Major Company of Voglibose Table 3. Major Company of Miglitol Table 4. Major Company of Other Table 5. Global α-Glucosidase Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 7. Global α-Glucosidase Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 8. Global α-Glucosidase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 9. Global α-Glucosidase Inhibitors Sales Market Share in Value by Type (2021-2026) Table 10. Global α-Glucosidase Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 11. Global α-Glucosidase Inhibitors Sales by Type (2027-2032) & (K Units) Table 12. Global α-Glucosidase Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 13. Global α-Glucosidase Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 14. Global α-Glucosidase Inhibitors Sales Market Share in Value by Type (2027-2032) Table 15. Global α-Glucosidase Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 16. North America α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 17. North America α-Glucosidase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 18. Europe α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 19. Europe α-Glucosidase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific α-Glucosidase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 23. Latin America α-Glucosidase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa α-Glucosidase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 26. α-Glucosidase Inhibitors Industry Trends Table 27. α-Glucosidase Inhibitors Industry Drivers Table 28. α-Glucosidase Inhibitors Industry Opportunities and Challenges Table 29. α-Glucosidase Inhibitors Industry Restraints Table 30. Global α-Glucosidase Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global α-Glucosidase Inhibitors Revenue Market Share by Company (2021-2026) Table 32. Global α-Glucosidase Inhibitors Sales by Company (2021-2026) & (K Units) Table 33. Global α-Glucosidase Inhibitors Sales Share by Company (2021-2026) Table 34. Global α-Glucosidase Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global α-Glucosidase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global α-Glucosidase Inhibitors Major Company Production Sites and Headquarters Table 37. Global α-Glucosidase Inhibitors Company, Product Type & Application Table 38. Global α-Glucosidase Inhibitors Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global α-Glucosidase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global α-Glucosidase Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global α-Glucosidase Inhibitors Sales by Region (2021-2026) & (K Units) Table 43. Global α-Glucosidase Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 44. Global α-Glucosidase Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 45. Global α-Glucosidase Inhibitors Sales Market Share in Value by Region (2021-2026) Table 46. Global α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global α-Glucosidase Inhibitors Sales by Region (2027-2032) & (K Units) Table 48. Global α-Glucosidase Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 49. Global α-Glucosidase Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 50. Global α-Glucosidase Inhibitors Sales Market Share in Value by Region (2027-2032) Table 51. Global α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global α-Glucosidase Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 54. Global α-Glucosidase Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 55. Global α-Glucosidase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 56. Global α-Glucosidase Inhibitors Sales Market Share in Value by Application (2021-2026) Table 57. Global α-Glucosidase Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 58. Global α-Glucosidase Inhibitors Sales by Application (2027-2032) & (K Units) Table 59. Global α-Glucosidase Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 60. Global α-Glucosidase Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 61. Global α-Glucosidase Inhibitors Sales Market Share in Value by Application (2027-2032) Table 62. Global α-Glucosidase Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 63. North America α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 64. North America α-Glucosidase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 65. Europe α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 66. Europe α-Glucosidase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific α-Glucosidase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 70. Latin America α-Glucosidase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa α-Glucosidase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 73. Bluepharma Company Information Table 74. Bluepharma Business Overview Table 75. Bluepharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bluepharma α-Glucosidase Inhibitors Product Portfolio Table 77. Bluepharma Recent Development Table 78. Glenmark Pharma Company Information Table 79. Glenmark Pharma Business Overview Table 80. Glenmark Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Glenmark Pharma α-Glucosidase Inhibitors Product Portfolio Table 82. Glenmark Pharma Recent Development Table 83. Lunan Pharma Company Information Table 84. Lunan Pharma Business Overview Table 85. Lunan Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Lunan Pharma α-Glucosidase Inhibitors Product Portfolio Table 87. Lunan Pharma Recent Development Table 88. Lupin Pharma Company Information Table 89. Lupin Pharma Business Overview Table 90. Lupin Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Lupin Pharma α-Glucosidase Inhibitors Product Portfolio Table 92. Lupin Pharma Recent Development Table 93. Strides Pharma Company Information Table 94. Strides Pharma Business Overview Table 95. Strides Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Strides Pharma α-Glucosidase Inhibitors Product Portfolio Table 97. Strides Pharma Recent Development Table 98. Bayer Company Information Table 99. Bayer Business Overview Table 100. Bayer α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Bayer α-Glucosidase Inhibitors Product Portfolio Table 102. Bayer Recent Development Table 103. Beijing SL Pharmaceutical Company Information Table 104. Beijing SL Pharmaceutical Business Overview Table 105. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 107. Beijing SL Pharmaceutical Recent Development Table 108. Cisen Pharmaceutical Company Information Table 109. Cisen Pharmaceutical Business Overview Table 110. Cisen Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Cisen Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 112. Cisen Pharmaceutical Recent Development Table 113. Hangzhou East China Pharmaceutical Company Information Table 114. Hangzhou East China Pharmaceutical Business Overview Table 115. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 117. Hangzhou East China Pharmaceutical Recent Development Table 118. Pfizer Company Information Table 119. Pfizer Business Overview Table 120. Pfizer α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Pfizer α-Glucosidase Inhibitors Product Portfolio Table 122. Pfizer Recent Development Table 123. Jinri Pharmaceutical (China) Company Information Table 124. Jinri Pharmaceutical (China) Business Overview Table 125. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product Portfolio Table 127. Jinri Pharmaceutical (China) Recent Development Table 128. Livzon Pharm Company Information Table 129. Livzon Pharm Business Overview Table 130. Livzon Pharm α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Livzon Pharm α-Glucosidase Inhibitors Product Portfolio Table 132. Livzon Pharm Recent Development Table 133. Luye Pharma Company Information Table 134. Luye Pharma Business Overview Table 135. Luye Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Luye Pharma α-Glucosidase Inhibitors Product Portfolio Table 137. Luye Pharma Recent Development Table 138. Nanjing Hicin Pharmaceutical Company Information Table 139. Nanjing Hicin Pharmaceutical Business Overview Table 140. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 142. Nanjing Hicin Pharmaceutical Recent Development Table 143. Shandong New Time Pharmaceutical Company Information Table 144. Shandong New Time Pharmaceutical Business Overview Table 145. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 147. Shandong New Time Pharmaceutical Recent Development Table 148. CSPC Ouyi Pharmaceutical Company Information Table 149. CSPC Ouyi Pharmaceutical Business Overview Table 150. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 152. CSPC Ouyi Pharmaceutical Recent Development Table 153. Weiao Pharmaceutical (Sichuan) Company Information Table 154. Weiao Pharmaceutical (Sichuan) Business Overview Table 155. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product Portfolio Table 157. Weiao Pharmaceutical (Sichuan) Recent Development Table 158. Sun Pharmaceutical Company Information Table 159. Sun Pharmaceutical Business Overview Table 160. Sun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Sun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 162. Sun Pharmaceutical Recent Development Table 163. SUN Pharma Company Information Table 164. SUN Pharma Business Overview Table 165. SUN Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. SUN Pharma α-Glucosidase Inhibitors Product Portfolio Table 167. SUN Pharma Recent Development Table 168. Takeda Company Information Table 169. Takeda Business Overview Table 170. Takeda α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Takeda α-Glucosidase Inhibitors Product Portfolio Table 172. Takeda Recent Development Table 173. YaoPharma Company Information Table 174. YaoPharma Business Overview Table 175. YaoPharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. YaoPharma α-Glucosidase Inhibitors Product Portfolio Table 177. YaoPharma Recent Development Table 178. Zhejiang Hisun Pharmaceutical Company Information Table 179. Zhejiang Hisun Pharmaceutical Business Overview Table 180. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 182. Zhejiang Hisun Pharmaceutical Recent Development Table 183. Zhejiang Jingxin Pharmaceutical Company Information Table 184. Zhejiang Jingxin Pharmaceutical Business Overview Table 185. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 187. Zhejiang Jingxin Pharmaceutical Recent Development Table 188. Zhejiang Medicine Company Information Table 189. Zhejiang Medicine Business Overview Table 190. Zhejiang Medicine α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 191. Zhejiang Medicine α-Glucosidase Inhibitors Product Portfolio Table 192. Zhejiang Medicine Recent Development Table 193. North America α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 194. North America α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 195. North America α-Glucosidase Inhibitors Sales Market Share by Country (2021-2026) Table 196. North America α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 197. North America α-Glucosidase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 198. North America α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. North America α-Glucosidase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 200. North America α-Glucosidase Inhibitors Market Share by Country (2021-2026) Table 201. North America α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. North America α-Glucosidase Inhibitors Market Share Forecast by Country (2027-2032) Table 203. Europe α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 204. Europe α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 205. Europe α-Glucosidase Inhibitors Sales Market Share by Country (2021-2026) Table 206. Europe α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 207. Europe α-Glucosidase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 208. Europe α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 209. Europe α-Glucosidase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 210. Europe α-Glucosidase Inhibitors Market Share by Country (2021-2026) Table 211. Europe α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 212. Europe α-Glucosidase Inhibitors Market Share Forecast by Country (2027-2032) Table 213. Asia-Pacific α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 214. Asia-Pacific α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 215. Asia-Pacific α-Glucosidase Inhibitors Sales Market Share by Country (2021-2026) Table 216. Asia-Pacific α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 217. Asia-Pacific α-Glucosidase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 218. Asia-Pacific α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 219. Asia-Pacific α-Glucosidase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 220. Asia-Pacific α-Glucosidase Inhibitors Market Share by Country (2021-2026) Table 221. Asia-Pacific α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 222. Asia-Pacific α-Glucosidase Inhibitors Market Share Forecast by Country (2027-2032) Table 223. Latin America α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 224. Latin America α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 225. Latin America α-Glucosidase Inhibitors Sales Market Share by Country (2021-2026) Table 226. Latin America α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 227. Latin America α-Glucosidase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 228. Latin America α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 229. Latin America α-Glucosidase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 230. Latin America α-Glucosidase Inhibitors Market Share by Country (2021-2026) Table 231. Latin America α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 232. Latin America α-Glucosidase Inhibitors Market Share Forecast by Country (2027-2032) Table 233. Middle East and Africa α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 234. Middle East and Africa α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 235. Middle East and Africa α-Glucosidase Inhibitors Sales Market Share by Country (2021-2026) Table 236. Middle East and Africa α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 237. Middle East and Africa α-Glucosidase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 238. Middle East and Africa α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 239. Middle East and Africa α-Glucosidase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 240. Middle East and Africa α-Glucosidase Inhibitors Market Share by Country (2021-2026) Table 241. Middle East and Africa α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 242. Middle East and Africa α-Glucosidase Inhibitors Market Share Forecast by Country (2027-2032) Table 243. Key Raw Materials Table 244. Raw Materials Key Suppliers Table 245. α-Glucosidase Inhibitors Distributors List Table 246. α-Glucosidase Inhibitors Customers List Table 247. Research Programs/Design for This Report Table 248. Authors List of This Report Table 249. Secondary Sources Table 250. Primary Sources List of Figures Figure 1. α-Glucosidase Inhibitors Image Figure 2. Global α-Glucosidase Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global α-Glucosidase Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global α-Glucosidase Inhibitors Sales (2021-2032) & (K Units) Figure 5. Acarbose Image Figure 6. Global Acarbose Sales YoY Growth (2021-2032) & (K Units) Figure 7. Voglibose Image Figure 8. Global Voglibose Sales YoY Growth (2021-2032) & (K Units) Figure 9. Miglitol Image Figure 10. Global Miglitol Sales YoY Growth (2021-2032) & (K Units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global α-Glucosidase Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global α-Glucosidase Inhibitors Market Share by Type 2025 VS 2032 Figure 15. North America α-Glucosidase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. North America α-Glucosidase Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Europe α-Glucosidase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Europe α-Glucosidase Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific α-Glucosidase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific α-Glucosidase Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Latin America α-Glucosidase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 22. Latin America α-Glucosidase Inhibitors Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa α-Glucosidase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa α-Glucosidase Inhibitors Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 α-Glucosidase Inhibitors Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital and Clinic Image Figure 28. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Pharmacy Image Figure 30. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global α-Glucosidase Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global α-Glucosidase Inhibitors Market Share by Application 2025 VS 2032 Figure 35. North America α-Glucosidase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 36. North America α-Glucosidase Inhibitors Sales Market Share in Value by Application in 2025 Figure 37. Europe α-Glucosidase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. Europe α-Glucosidase Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific α-Glucosidase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific α-Glucosidase Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Latin America α-Glucosidase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Latin America α-Glucosidase Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa α-Glucosidase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa α-Glucosidase Inhibitors Sales Market Share in Value by Application in 2025 Figure 45. North America α-Glucosidase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America α-Glucosidase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America α-Glucosidase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America α-Glucosidase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe α-Glucosidase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe α-Glucosidase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe α-Glucosidase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe α-Glucosidase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific α-Glucosidase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific α-Glucosidase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific α-Glucosidase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific α-Glucosidase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America α-Glucosidase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America α-Glucosidase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America α-Glucosidase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America α-Glucosidase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa α-Glucosidase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa α-Glucosidase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa α-Glucosidase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa α-Glucosidase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. α-Glucosidase Inhibitors Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. α-Glucosidase Inhibitors Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Acarbose
  • Voglibose
  • Miglitol
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Bluepharma
  • Glenmark Pharma
  • Lunan Pharma
  • Lupin Pharma
  • Strides Pharma
  • Bayer
  • Beijing SL Pharmaceutical
  • Cisen Pharmaceutical
  • Hangzhou East China Pharmaceutical
  • Pfizer
  • Jinri Pharmaceutical (China)
  • Livzon Pharm
  • Luye Pharma
  • Nanjing Hicin Pharmaceutical
  • Shandong New Time Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Weiao Pharmaceutical (Sichuan)
  • Sun Pharmaceutical
  • SUN Pharma
  • Takeda
  • YaoPharma
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Jingxin Pharmaceutical
  • Zhejiang Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global α-Glucosidase Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global α-Glucosidase Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 α-Glucosidase Inhibitors Market by Type
  6. 1.3.1 Acarbose
  7. 1.3.2 Voglibose
  8. 1.3.3 Miglitol
  9. 1.3.4 Other
  10. 1.4 Global α-Glucosidase Inhibitors Market Size by Type
  11. 1.4.1 Global α-Glucosidase Inhibitors Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global α-Glucosidase Inhibitors Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global α-Glucosidase Inhibitors Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America α-Glucosidase Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe α-Glucosidase Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific α-Glucosidase Inhibitors Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America α-Glucosidase Inhibitors Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa α-Glucosidase Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 α-Glucosidase Inhibitors Industry Trends
  2. 2.2 α-Glucosidase Inhibitors Industry Drivers
  3. 2.3 α-Glucosidase Inhibitors Industry Opportunities and Challenges
  4. 2.4 α-Glucosidase Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by α-Glucosidase Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by α-Glucosidase Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by α-Glucosidase Inhibitors Price (2021-2026)
  4. 3.4 Global α-Glucosidase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global α-Glucosidase Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global α-Glucosidase Inhibitors Company, Product Type & Application
  7. 3.7 Global α-Glucosidase Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global α-Glucosidase Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 α-Glucosidase Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 α-Glucosidase Inhibitors Tier 1, Tier 2, and Tier 3
4 α-Glucosidase Inhibitors Regional Status and Outlook
  1. 4.1 Global α-Glucosidase Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global α-Glucosidase Inhibitors Historic Market Size by Region
  3. 4.2.1 Global α-Glucosidase Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global α-Glucosidase Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global α-Glucosidase Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global α-Glucosidase Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global α-Glucosidase Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global α-Glucosidase Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global α-Glucosidase Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 α-Glucosidase Inhibitors by Application
  1. 5.1 α-Glucosidase Inhibitors Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global α-Glucosidase Inhibitors Market Size by Application
  6. 5.2.1 Global α-Glucosidase Inhibitors Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global α-Glucosidase Inhibitors Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global α-Glucosidase Inhibitors Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America α-Glucosidase Inhibitors Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe α-Glucosidase Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific α-Glucosidase Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America α-Glucosidase Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa α-Glucosidase Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bluepharma
  2. 6.1.1 Bluepharma Company Information
  3. 6.1.2 Bluepharma Business Overview
  4. 6.1.3 Bluepharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bluepharma α-Glucosidase Inhibitors Product Portfolio
  6. 6.1.5 Bluepharma Recent Developments
  7. 6.2 Glenmark Pharma
  8. 6.2.1 Glenmark Pharma Company Information
  9. 6.2.2 Glenmark Pharma Business Overview
  10. 6.2.3 Glenmark Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Glenmark Pharma α-Glucosidase Inhibitors Product Portfolio
  12. 6.2.5 Glenmark Pharma Recent Developments
  13. 6.3 Lunan Pharma
  14. 6.3.1 Lunan Pharma Company Information
  15. 6.3.2 Lunan Pharma Business Overview
  16. 6.3.3 Lunan Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Lunan Pharma α-Glucosidase Inhibitors Product Portfolio
  18. 6.3.5 Lunan Pharma Recent Developments
  19. 6.4 Lupin Pharma
  20. 6.4.1 Lupin Pharma Company Information
  21. 6.4.2 Lupin Pharma Business Overview
  22. 6.4.3 Lupin Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Lupin Pharma α-Glucosidase Inhibitors Product Portfolio
  24. 6.4.5 Lupin Pharma Recent Developments
  25. 6.5 Strides Pharma
  26. 6.5.1 Strides Pharma Company Information
  27. 6.5.2 Strides Pharma Business Overview
  28. 6.5.3 Strides Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Strides Pharma α-Glucosidase Inhibitors Product Portfolio
  30. 6.5.5 Strides Pharma Recent Developments
  31. 6.6 Bayer
  32. 6.6.1 Bayer Company Information
  33. 6.6.2 Bayer Business Overview
  34. 6.6.3 Bayer α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Bayer α-Glucosidase Inhibitors Product Portfolio
  36. 6.6.5 Bayer Recent Developments
  37. 6.7 Beijing SL Pharmaceutical
  38. 6.7.1 Beijing SL Pharmaceutical Company Information
  39. 6.7.2 Beijing SL Pharmaceutical Business Overview
  40. 6.7.3 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  42. 6.7.5 Beijing SL Pharmaceutical Recent Developments
  43. 6.8 Cisen Pharmaceutical
  44. 6.8.1 Cisen Pharmaceutical Company Information
  45. 6.8.2 Cisen Pharmaceutical Business Overview
  46. 6.8.3 Cisen Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Cisen Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  48. 6.8.5 Cisen Pharmaceutical Recent Developments
  49. 6.9 Hangzhou East China Pharmaceutical
  50. 6.9.1 Hangzhou East China Pharmaceutical Company Information
  51. 6.9.2 Hangzhou East China Pharmaceutical Business Overview
  52. 6.9.3 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  54. 6.9.5 Hangzhou East China Pharmaceutical Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Pfizer α-Glucosidase Inhibitors Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Jinri Pharmaceutical (China)
  62. 6.11.1 Jinri Pharmaceutical (China) Company Information
  63. 6.11.2 Jinri Pharmaceutical (China) Business Overview
  64. 6.11.3 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product Portfolio
  66. 6.11.5 Jinri Pharmaceutical (China) Recent Developments
  67. 6.12 Livzon Pharm
  68. 6.12.1 Livzon Pharm Company Information
  69. 6.12.2 Livzon Pharm Business Overview
  70. 6.12.3 Livzon Pharm α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Livzon Pharm α-Glucosidase Inhibitors Product Portfolio
  72. 6.12.5 Livzon Pharm Recent Developments
  73. 6.13 Luye Pharma
  74. 6.13.1 Luye Pharma Company Information
  75. 6.13.2 Luye Pharma Business Overview
  76. 6.13.3 Luye Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Luye Pharma α-Glucosidase Inhibitors Product Portfolio
  78. 6.13.5 Luye Pharma Recent Developments
  79. 6.14 Nanjing Hicin Pharmaceutical
  80. 6.14.1 Nanjing Hicin Pharmaceutical Company Information
  81. 6.14.2 Nanjing Hicin Pharmaceutical Business Overview
  82. 6.14.3 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  84. 6.14.5 Nanjing Hicin Pharmaceutical Recent Developments
  85. 6.15 Shandong New Time Pharmaceutical
  86. 6.15.1 Shandong New Time Pharmaceutical Company Information
  87. 6.15.2 Shandong New Time Pharmaceutical Business Overview
  88. 6.15.3 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  90. 6.15.5 Shandong New Time Pharmaceutical Recent Developments
  91. 6.16 CSPC Ouyi Pharmaceutical
  92. 6.16.1 CSPC Ouyi Pharmaceutical Company Information
  93. 6.16.2 CSPC Ouyi Pharmaceutical Business Overview
  94. 6.16.3 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  96. 6.16.5 CSPC Ouyi Pharmaceutical Recent Developments
  97. 6.17 Weiao Pharmaceutical (Sichuan)
  98. 6.17.1 Weiao Pharmaceutical (Sichuan) Company Information
  99. 6.17.2 Weiao Pharmaceutical (Sichuan) Business Overview
  100. 6.17.3 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product Portfolio
  102. 6.17.5 Weiao Pharmaceutical (Sichuan) Recent Developments
  103. 6.18 Sun Pharmaceutical
  104. 6.18.1 Sun Pharmaceutical Company Information
  105. 6.18.2 Sun Pharmaceutical Business Overview
  106. 6.18.3 Sun Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Sun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  108. 6.18.5 Sun Pharmaceutical Recent Developments
  109. 6.19 SUN Pharma
  110. 6.19.1 SUN Pharma Company Information
  111. 6.19.2 SUN Pharma Business Overview
  112. 6.19.3 SUN Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 SUN Pharma α-Glucosidase Inhibitors Product Portfolio
  114. 6.19.5 SUN Pharma Recent Developments
  115. 6.20 Takeda
  116. 6.20.1 Takeda Company Information
  117. 6.20.2 Takeda Business Overview
  118. 6.20.3 Takeda α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Takeda α-Glucosidase Inhibitors Product Portfolio
  120. 6.20.5 Takeda Recent Developments
  121. 6.21 YaoPharma
  122. 6.21.1 YaoPharma Company Information
  123. 6.21.2 YaoPharma Business Overview
  124. 6.21.3 YaoPharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 YaoPharma α-Glucosidase Inhibitors Product Portfolio
  126. 6.21.5 YaoPharma Recent Developments
  127. 6.22 Zhejiang Hisun Pharmaceutical
  128. 6.22.1 Zhejiang Hisun Pharmaceutical Company Information
  129. 6.22.2 Zhejiang Hisun Pharmaceutical Business Overview
  130. 6.22.3 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  132. 6.22.5 Zhejiang Hisun Pharmaceutical Recent Developments
  133. 6.23 Zhejiang Jingxin Pharmaceutical
  134. 6.23.1 Zhejiang Jingxin Pharmaceutical Company Information
  135. 6.23.2 Zhejiang Jingxin Pharmaceutical Business Overview
  136. 6.23.3 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  138. 6.23.5 Zhejiang Jingxin Pharmaceutical Recent Developments
  139. 6.24 Zhejiang Medicine
  140. 6.24.1 Zhejiang Medicine Company Information
  141. 6.24.2 Zhejiang Medicine Business Overview
  142. 6.24.3 Zhejiang Medicine α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Zhejiang Medicine α-Glucosidase Inhibitors Product Portfolio
  144. 6.24.5 Zhejiang Medicine Recent Developments
7 North America by Country
  1. 7.1 North America α-Glucosidase Inhibitors Sales by Country
  2. 7.1.1 North America α-Glucosidase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America α-Glucosidase Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America α-Glucosidase Inhibitors Market Size by Country
  6. 7.2.1 North America α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America α-Glucosidase Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe α-Glucosidase Inhibitors Sales by Country
  2. 8.1.1 Europe α-Glucosidase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe α-Glucosidase Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe α-Glucosidase Inhibitors Market Size by Country
  6. 8.2.1 Europe α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe α-Glucosidase Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific α-Glucosidase Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific α-Glucosidase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific α-Glucosidase Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific α-Glucosidase Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific α-Glucosidase Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America α-Glucosidase Inhibitors Sales by Country
  2. 10.1.1 South America α-Glucosidase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America α-Glucosidase Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America α-Glucosidase Inhibitors Market Size by Country
  6. 10.2.1 South America α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America α-Glucosidase Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa α-Glucosidase Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa α-Glucosidase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa α-Glucosidase Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa α-Glucosidase Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa α-Glucosidase Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa α-Glucosidase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa α-Glucosidase Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa α-Glucosidase Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 α-Glucosidase Inhibitors Value Chain Analysis
  2. 12.1.1 α-Glucosidase Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 α-Glucosidase Inhibitors Production Mode & Process
  7. 12.2 α-Glucosidase Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 α-Glucosidase Inhibitors Distributors
  10. 12.2.3 α-Glucosidase Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst